AstraZeneca will join Boehringer Ingelheim in capping out-of-pocket costs for its inhaler products at $35 per month, the company announced Monday (March 18). The move comes after Senate health committee Chair Bernie Sanders (I-VT) and other Senate Democrats launched an investigation into disparities in inhaler pricing between the United States and other countries. Lawmakers' pricing data reveal a stark contrast: AstraZeneca's Breztri Aerosphere inhaler is currently priced at $645 in the United States, yet it's only $49 in the United...